Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Azacitidine After Reduced-Intensity Allogeneic Transplant for AML
2007-006475-36Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Feb 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in acute myeloid leukemia (AML), sponsored by University of Birmingham. Primary endpoint: Tolerability of azacitidine post transplant. Started Feb 2008; status: completed.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2007-006475-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006475-36.